Home › Funds › Affinity Asset Advisors, LLC › ANRO
Affinity Asset Advisors, LLC position in ANRO
ALTO NEUROSCIENCE INC · Health Care
Affinity Asset Advisors, LLC reported holding 643,343 shares of ANRO (ALTO NEUROSCIENCE INC) in its Q3 2026 13F filing — a position valued at US$16.4M, representing 0.76% of its reported portfolio and ranking #34 among its reported holdings. Affinity Asset Advisors, LLC has disclosed ANRO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Affinity Asset Advisors, LLC's ANRO position evolved
Affinity Asset Advisors, LLC first disclosed a stake in ANRO in Q1 2026 at 500,000 shares (US$11.2M). The position peaked in Q2 2026 at 850,000 shares, worth US$22.4M. Across 3 filings, Affinity Asset Advisors, LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 643,343 shares valued at US$16.4M — a reduction of -206,657 shares quarter over quarter.. Notable position changes include a 70% increase in Q2 2026 (shares fell 3% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 500.00K | $11.24M | New |
| Q2 2026 | 850.00K | $22.43M | Add |
| Q3 2026 | 643.34K | $16.42M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ANRO and 13F data
ANRO (ALTO NEUROSCIENCE INC) is a Health Care company. 62 other funds we track also report a position in ANRO — the largest reported positions include Alpha Wave Global, LP (US$94.7M), Commodore Capital LP (US$71.9M), Spruce Street Capital LP (US$42.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ANRO
- Alpha Wave Global, LP 3.71M sh · $94.66M · Q3 2026
- Commodore Capital LP 2.72M sh · $71.87M · Q2 2026
- Spruce Street Capital LP 1.68M sh · $42.80M · Q3 2026
- PERCEPTIVE ADVISORS LLC 1.61M sh · $42.49M · Q2 2026
- Vivo Capital, LLC 1.36M sh · $34.72M · Q3 2026
- ARMISTICE CAPITAL, LLC 864.00K sh · $22.80M · Q2 2026
- Vestal Point Capital, LP 785.00K sh · $20.72M · Q2 2026
- 72 Investment Holdings, LLC 667.78K sh · $17.62M · Q2 2026
- Venrock Adviser, LLC 500.00K sh · $13.20M · Q2 2026
- Parkman Healthcare Partners LLC 429.04K sh · $11.32M · Q2 2026
- Ikarian Capital, LLC 407.34K sh · $10.75M · Q2 2026
- Saturn V Capital Management LP 182.83K sh · $4.82M · Q2 2026
More on Affinity Asset Advisors, LLC
FAQ
How long has Affinity Asset Advisors, LLC held ANRO?
Affinity Asset Advisors, LLC has disclosed ANRO holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Affinity Asset Advisors, LLC's current position in ANRO?
As of Q3 2026, Affinity Asset Advisors, LLC holds 643.34K shares of ANRO (ALTO NEUROSCIENCE INC), valued at $16.42M, representing 0.76% of its reported portfolio and ranking #34.
Has Affinity Asset Advisors, LLC been buying or selling ANRO?
In the latest 13F filing (Q3 2026), Affinity Asset Advisors, LLC reduced its position in ANRO. The position peaked in Q2 2026 at 850.00K shares.
Which other funds hold ANRO?
Other major institutional holders of ANRO include Alpha Wave Global, LP, Commodore Capital LP, Spruce Street Capital LP, among 62 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.